Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: A review of 110 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 7, 2007, Pages 916-920

  Fai, D ^a,c   Cassano, N ^b   Vena, G A ^b  

^a Presidio Ospedaliero 'F Ferrari'   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NONE   (Italy)

Author keywords

Combined treatment; Narrow band UVB; Phototherapy; Tacrolimus ointment; Vitiligo

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID; FLUTICASONE PROPIONATE; KHELLIN; METHOXSALEN; MOMETASONE FUROATE; NUTRACEUTICAL; PIMECROLIMUS; TACROLIMUS;

ADULT; AGED; ATROPHY; CHRONIC DISEASE; CONTROLLED STUDY; EXCIMER LASER; FACE; FEMALE; FOLLICULITIS; HUMAN; INFORMED CONSENT; LIMB; MAJOR CLINICAL STUDY; MALE; OINTMENT; OPEN STUDY; PATIENT SELECTION; PHOTOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; REVIEW; SKIN PIGMENTATION; TELANGIECTASIA; TREATMENT DURATION; TREATMENT RESPONSE; TRUNK; ULTRAVIOLET B RADIATION; VITILIGO;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TACROLIMUS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITILIGO;

EID: 34547135952     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.02101.x     Document Type: Review

References (27)

1. Hautmann G, Panconesi E. Vitiligo: A psychologically influenced and influencing disease. Clin Dermatol 1997; 15: 879-890.
2. Firooz A, Bouzari N, Fallah N et al. What patients with vitiligo believe about their condition. Int J Dermatol 2004; 43: 811-814.
3. Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005; 152: 1165-1172.
4. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev 2006; 25: CD003263.
5. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet-B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001; 44: 999-1003.
6. Gambichler T, Breuckmann F, Boms S et al. Narrow-band UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 2005; 52: 660-670.
7. Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol 2005; 30: 332-336.
8. Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 175-177.
9. El Mofty M, Mostafa W, Esmat S et al. Narrow-band Ultraviolet B 311 nm in the treatment of vitiligo: Two right-left comparison studies. Photodermatol Photoimmunol Photomed 2006; 22: 6-11.
10. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-791.
11. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: Results of a prospective patient series. Cutis 2003; 71: 158-162.
12. Lepe V, Moncada B, Castanedo-Cazares JP et al. A double-blind randomized trial of 0.1% tacrolimus vs. 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-585.
13. Silverberg NB, Lin P, Travis L et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. J Am Acad Dermatol 2004; 51: 760-766.
14. Kostovic K, Pasic A. New treatment modalities for vitiligo: Focus on topical immunomodulators. Drugs 2005, 65 447-459.
15. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 2003; 19: 35-36.
16. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: A pilot study. Dermatol Surg 2004; 30: 130-135.
17. Passeron T, Ostovari N, Zakaria W et al. Topical tacrolimus and the 308-nm excimer laser: A synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-1069.
18. Van Geel N, Vander Haeghen Y, Ongenae K, Naeyaert J-M. A new digital image analysis system useful for surface assessment of vitiligo lesions in transplantation studies. Eur J Dermatol 2004; 14: 150-155.
19. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrow-band UV-B Plus 0.1% tacrolimus ointment with narrow-band UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142: 927-929.
20. Grimes PE, Morris R, Avaniss-Aghajani E et al. Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
21. Lan CC, Chen GS, Chiou MH et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: Possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-505.
22. Ostovari N, Passeron T, Lacour JP, Ortonne JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142: 252-253.
23. Yarosh DB, Pena AV, Nay SL et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-1025.
24. Tran C, Lubbe J, Sorg O et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211: 341-347.
25. Ogawa Y, Adachi A, Tomita Y. The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with complications of idiopathic leukopenia. J Dermatol 2003; 30: 805-809.
26. Mayuzumi N, Ikeda S, Kawada H, Ogawa H. Effects of drugs and anticytokine antibodies on expression of ATP2A2 and ATP2C1 in cultured normal human keratinocytes. Br J Dermatol 2005; 152: 920-924.
27. Lan CC, Yu HS, Wu CS et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol 2005; 153: 725-732.